Get the Stockscreener App
1.19
0.93%
0.011
Barinthus Biotherapeutics Plc Adr stock is traded at $1.19, with a volume of 14,889.
It is up +0.93% in the last 24 hours and down -0.42% over the past month.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.
See More
Previous Close:
$1.179
Open:
$1.15
24h Volume:
14,889
Relative Volume:
0.01
Market Cap:
$48.45M
Revenue:
$13.42M
Net Income/Loss:
$-73.35M
P/E Ratio:
-0.6198
EPS:
-1.92
Net Cash Flow:
$-56.34M
1W Performance:
+7.69%
1M Performance:
-0.42%
6M Performance:
+16.10%
1Y Performance:
-0.83%
1-Day Range:
$1.11
$1.19
1-Week Range:
$1.04
$1.28
52-Week Range:
$0.64
$2.92
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Company Profile
Name
Barinthus Biotherapeutics Plc Adr
Sector
Industry
Phone
44 (0) 1865 818808
Address
20400 CENTURY BLVD, GERMANTOWN
Compare BRNS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BRNS
Barinthus Biotherapeutics Plc Adr
|
1.19 | 42.75M | 13.42M | -73.35M | -56.34M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
377.45 | 96.56B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.64 | 60.08B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
555.93 | 61.15B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
702.28 | 44.66B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
326.38 | 36.23B | 3.81B | -644.79M | -669.77M | -6.24 |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-25-21 | Initiated | Jefferies | Buy |
| May-25-21 | Initiated | Morgan Stanley | Overweight |
| May-25-21 | Initiated | William Blair | Outperform |
| May-24-21 | Initiated | H.C. Wainwright | Buy |
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Latest News
37,450 Shares in Barinthus Biotherapeutics PLC Sponsored ADR $BRNS Acquired by HighTower Advisors LLC - Defense World
Raymond James Financial Inc. Raises Stock Position in Virtus Terranova U.S. Quality Momentum ETF $JOET - Defense World
Freehold Royalties (TSE:FRU) Stock Price Crosses Above Two Hundred Day Moving Average – What’s Next? - Defense World
Martinrea International (TSE:MRE) Share Price Passes Above Two Hundred Day Moving Average – Should You Sell? - Defense World
PNC Financial Services Group Inc. Increases Stake in United Microelectronics Corporation (NYSE:UMC) - Defense World
BRNS’s Market Whiplash: 50.99% YTD Rise, 152.41% Rise in 30 Days - investchronicle.com
BRNS stock touches 52-week low at $0.8 amid market volatility - Investing.com
Barinthus Biotherapeutics PLC Sponsored ADR (BRNS) Upgraded to Strong Buy: Here's Why - Nasdaq
Barinthus Bio shifts focus, cuts workforce to extend cash runway - Investing.com
The big rebrand: Why these 4 biopharmas changed their name this year - PharmaVoice
Mexico Shingles Vaccine Market Size & Outlook, 2023-2030 - Grand View Research
Why Sarepta Therapeutics Shares Are Trading Higher By Around 35%; Here Are 20 Stocks Moving Premarket - Investing.com UK
Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance
Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time - MarketBeat
Barinthus Biotherapeutics Plc Adr Stock (BRNS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):